EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Linzagolix for Japanese women with uterine fibroids: a randomized, double-blind, placebo-controlled, phase 3 trial

Tasuku Harada, Yutaka Osuga, Hideomi Takahashi, Asuka Kawai, Fumiya Shimamura, KLH2302 Investigators

F&S Reports · 2026-10 · 7 (5) · 417-424

DOI: 10.1016/j.xfre.2026.07.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift F&S Reports, 2026-10. Verfasst von Tasuku Harada und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Faculty of Medicine, Tottori University, Tottori, Japan. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kissei Pharmaceutical Co Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the efficacy, safety, and pharmacodynamics of linzagolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in patients with heavy menstrual bleeding (HMB) and pain because of uterine fibroids.

Design

Phase 3, multicenter, placebo-controlled, randomized, double-blind, parallel-group, confirmatory study (NCT05445167). Subjects: Premenopausal Japanese women with HMB and moderate-to-severe pain because of uterine fibroids.

Intervention

Patients were randomized 1:1 to once-daily linzagolix 200 mg (n = 48) or placebo (n = 41) for 12 weeks. Main Outcome Measures: The primary endpoints were the proportion of patients with a total pictorial blood loss assessment chart (PBAC) score

Schlagwörter

Stichwörter der Autor:innen

Gonadotropin-releasing hormone receptor antagonistheavy menstrual bleedinglinzagolixpainuterine fibroids

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Faculty of Medicine, Tottori University, Tottori, Japan.
  • Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Clinical Research Department, Kissei Pharmaceutical Co., Ltd., Tokyo, Japan.
  • Clinical Projects Management Department, Kissei Pharmaceutical Co., Ltd., Tokyo, Japan.

Förderung

  • Kissei Pharmaceutical Co Ltd

Zitieren

APA

Harada, T., Osuga, Y., Takahashi, H., Kawai, A., Shimamura, F., & KLH2302 Investigators (2026). Linzagolix for Japanese women with uterine fibroids: a randomized, double-blind, placebo-controlled, phase 3 trial. F&S Reports, 7(5), 417-424. https://doi.org/10.1016/j.xfre.2026.07.003

Vancouver

Harada T, Osuga Y, Takahashi H, Kawai A, Shimamura F, KLH2302 Investigators. Linzagolix for Japanese women with uterine fibroids: a randomized, double-blind, placebo-controlled, phase 3 trial. F&S Reports. 2026;7(5):417-424. doi:10.1016/j.xfre.2026.07.003

BibTeX
@article{Harada2026,
  author = {Harada, Tasuku and Osuga, Yutaka and Takahashi, Hideomi and Kawai, Asuka and Shimamura, Fumiya and KLH2302 Investigators, KLH2302 Investigators},
  title = {Linzagolix for Japanese women with uterine fibroids: a randomized, double-blind, placebo-controlled, phase 3 trial},
  journal = {F&S Reports},
  year = {2026},
  volume = {7},
  number = {5},
  pages = {417--424},
  doi = {10.1016/j.xfre.2026.07.003}
}
Kostenlos starten →